Healthcare Roundup – FDA OK generic version of Lilly’s Jardiance, Endra re-ups with GE Healthcare

医疗保健精选——礼来Jardiance仿制药获批,Endra与GE医疗合作
Published on: January 15, 2020
Author: Amy Liu

FDA OK generic version of Lilly’s Jardiance

  • The FDA tentatively approves Alembic Pharmaceuticals’ marketing application for its generic version of Eli Lilly’s (NYSE:LLY) type 2 diabetes med Jardiance (empagliflozin), the first generic OK’d in the U.S.
  • Tentative approval means that Alembic’s marketing application met the requirements for approval, but patent issues need to be resolved before full approval is granted.
  • LLY is down a fraction after hours.

Endra re-ups with GE Healthcare; shares ahead 2% premarket

  • ENDRA Life Sciences (NASDAQ:NDRA) has renewed its collaboration agreement with GE Healthcare for another year. Under the terms of the partnership, the latter will continue to support the commercialization of ENDRA’s TAEUS technology for use in a fatty liver application, including facilitating introductions to its clinical ultrasound customers.
  • Shares up 2% premarket on light volume.

Rockwell Medical up 14% premarket on Triferic deal in India

  • Thinly traded micro cap Rockwell Medical (NASDAQ:RMTI) is up 14% premarket on increased volume in reaction to its license and supply agreement with a subsidiary of Sun Pharmaceutical Industries Ltd. (OTCPK:SMPQY) for the exclusive commercialization of Triferic (ferric pyrophosphate citrate) in India.
  • Under the terms of the deal, Rockwell will receive an upfront fee, milestones and royalties on net sales. Specific financial terms are not disclosed.

Astellas completes acquisition of Audentes Therapeutics

  • Astellas Pharma (OTCPK:ALPMF) has finalized its ~$3B takeover of Audentes Therapeutics (NASDAQ:BOLD) announced last month.
  • It will operate as a wholly owned subsidiary led by Natalie Holles. A key goal for this year is the filing of a U.S. marketing application for AT132 for X-linked myotubular myopathy.

Twist Bio teams up with Schrödinger in drug discovery

  • Twist Bioscience (NASDAQ:TWST) collaborates with Schrödinger, Inc., to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets.
  • Under the terms of the agreement, Schrödinger will use its physics-based computational platform to model functional antibody segments that bind to a particular GPCR receptor.
  • Twist Biopharma, a division of Twist Bioscience, will use its silicon-based DNA synthesis platform to generate a large number of defined antibody sequences that can then be taken into proof-of-concept and preclinical development.
  • The companies will collaborate on any commercial opportunities generated by the work together.

Biotechnology Genomics Life Science